IMVT-1402-3101 is a clinical study by Immunovant evaluating IMVT-1402, a promising investigational therapy designed to reduce harmful antibodies that drive autoimmune diseases.

The trial aims to assess its safety and effectiveness in improving symptoms and long-term disease control for patients who still struggle despite current treatments—offering hope for a more targeted and sustained approach to managing chronic autoimmune conditions.

​

To qualify, participants generally must:

​​​

• Age: 18 years or older

​

• Diagnosis

  • Generalized Myasthenia Gravis (gMG) with:

    • MGFA Class II–IVa

    • Confirmed clinical diagnosis

​​​

• Disease severity:

  • MG-ADL score ≥ 6 at screening and baseline

​​

• Ability to consent and comply:

  • Must understand study requirements and sign informed consent